SKU: D106  / 
    CAS Number: 157-03-9


    $89.00 - $311.00

    6-Diazo-5-oxo-L-norleucine (syn: DON) is a natural antibiotic and glutamine antagonist originally isolated from Streptomyces sp from a Peruvian soil sample in 1954.  The compound has anti-cancer properties, disrupting the mitochondrial internal membrane structures of the neuroendocrine tumor cell line BON and causing DNA single-strand breaks. Prodrug strategies have been developed to enhance delivery of active compound in vivo due to GI toxicity.  It can act synergistically with L-asparaginase to inhibit U251, U87, and SF767 glioblastoma cells. It can be used to study the enzymes that use glutamine such as carbamoyl phosphate synthase and cytidine triphosphate synthase 1(s) (CTPS1) and various glutaminases.  

    6-Diazo-5-oxo-L-norleucine is soluble in water, DMSO and methanol.

    Research use only; not for human or animal use.


    Molecular Formula  C6H9N303
    Mechanism of Action 6-Diazo-5-oxo-L-norleucine is an inhibitor of glutamine synthetase-glutamine (amide)-2-oxoglutarate aminotransferase.
    Cancer Applications 6-Diazo-5-oxo-L-norleucine has antitumor activity, causing disruption in the mitochondrial internal membrane structures of the neuroendocrine tumor cell line BON concomitant with single-strand breaks in DNA.  In early preclinical cancer models, DON inhibited the growth of multiple cancer cell lines in culture.

    Cervantes-Madrid D, Romero Y, Dueñas-González A(2015)  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy. BioMed Res. Intl. Article ID 690492

    Dion HW et al (1954)  6-Diazo-5-oxo-L-norleucine, a new tumor inhibitory substance. II: Isolation and characterization. Antibiot Chemother. 78:3075

    Hiramoto K et al (1996)  DNA strand cleavage by tumor-inhibiting antibiotic 6-diazo-5-oxo-L-norleucine. Mutat Res. 360:95

    Lemberg KM, Vornov JJ, Rais R, Slusher BS (2018)  We're not “DON” yet: Optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucineMol Cancer Ther 1 17 (9):1824–1832

    Wu et al (1999)  A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria. Eur J Cancer 35:1155